Line 50: | Line 50: | ||
<nav class="cd-secondary-nav" id="designtab" ng-show="subnav == 'design'"> | <nav class="cd-secondary-nav" id="designtab" ng-show="subnav == 'design'"> | ||
<ul> | <ul> | ||
− | <li><a href="/Team:Waterloo/InDepthDesign/HowItWorks">HOW IT WORKS</a></li> | + | <li><a class="paragraph-medium" href="/Team:Waterloo/InDepthDesign/HowItWorks">HOW IT WORKS</a></li> |
<li><a class="paragraph-medium" href="/Team:Waterloo/Software">PREMATURE STOP CODON</a></li> | <li><a class="paragraph-medium" href="/Team:Waterloo/Software">PREMATURE STOP CODON</a></li> | ||
<li><a class="paragraph-medium" href="/Team:Waterloo/InDepthDesign/PromoterSelection">PROMOTER SELECTION</a></li> | <li><a class="paragraph-medium" href="/Team:Waterloo/InDepthDesign/PromoterSelection">PROMOTER SELECTION</a></li> | ||
Line 61: | Line 61: | ||
<nav class="cd-secondary-nav" id="resultstab" ng-show="subnav == 'results'"> | <nav class="cd-secondary-nav" id="resultstab" ng-show="subnav == 'results'"> | ||
<ul> | <ul> | ||
− | <li><a href="https://2016.igem.org/Team:Waterloo/Proof">PROOF OF CONCEPT</a></li> | + | <li><a class="paragraph-medium" href="https://2016.igem.org/Team:Waterloo/Proof">PROOF OF CONCEPT</a></li> |
− | <li><a href="/Team:Waterloo/Results/PlasmidLoss">GENE RETENTION</a></li> | + | <li><a class="paragraph-medium" href="/Team:Waterloo/Results/PlasmidLoss">GENE RETENTION</a></li> |
− | <li><a href="/Team:Waterloo/Results/PromoterAnalysis">PROMOTER ANALYSIS</a></li> | + | <li><a class="paragraph-medium" href="/Team:Waterloo/Results/PromoterAnalysis">PROMOTER ANALYSIS</a></li> |
</ul> | </ul> | ||
Line 71: | Line 71: | ||
<ul> | <ul> | ||
<li><a href="/Team:Waterloo/Parts">PARTS</a></li> | <li><a href="/Team:Waterloo/Parts">PARTS</a></li> | ||
− | <li><a href="/Team:Waterloo/Experiments">PROTOCOLS</a></li> | + | <li><a class="paragraph-medium" href="/Team:Waterloo/Experiments">PROTOCOLS</a></li> |
− | <li><a href="/Team:Waterloo/Notebook">NOTEBOOK</a></li> | + | <li><a class="paragraph-medium" href="/Team:Waterloo/Notebook">NOTEBOOK</a></li> |
− | <li><a href="/Team:Waterloo/Safety">SAFETY</a></li> | + | <li><a class="paragraph-medium" href="/Team:Waterloo/Safety">SAFETY</a></li> |
</ul> | </ul> | ||
</nav> | </nav> | ||
Line 79: | Line 79: | ||
<nav class="cd-secondary-nav" id="practices" ng-show="subnav == 'practices'"> | <nav class="cd-secondary-nav" id="practices" ng-show="subnav == 'practices'"> | ||
<ul> | <ul> | ||
− | <li><a href="/Team:Waterloo/HP/Silver">SILVER</a></li> | + | <li><a class="paragraph-medium" href="/Team:Waterloo/HP/Silver">SILVER</a></li> |
− | <li><a href="/Team:Waterloo/HP/Gold">GOLD</a></li> | + | <li><a class="paragraph-medium" href="/Team:Waterloo/HP/Gold">GOLD</a></li> |
− | <li><a href="/Team:Waterloo/Engagement">OVERVIEW</a></li> | + | <li><a class="paragraph-medium" href="/Team:Waterloo/Engagement">OVERVIEW</a></li> |
− | <li><a href="/Team:Waterloo/Engagement/Gender_Equity">GENDER EQUITY</a></li> | + | <li><a class="paragraph-medium" href="/Team:Waterloo/Engagement/Gender_Equity">GENDER EQUITY</a></li> |
− | <li><a href="/Team:Waterloo/Engagement/Ethics">ETHICS</a></li> | + | <li><a class="paragraph-medium" href="/Team:Waterloo/Engagement/Ethics">ETHICS</a></li> |
− | <li><a href="/Team:Waterloo/Engagement/Collaboration">COLLABORATIONS</a></li> | + | <li><a class="paragraph-medium" href="/Team:Waterloo/Engagement/Collaboration">COLLABORATIONS</a></li> |
− | <li><a href="/Team:Waterloo/Engagement/Openness">OPENNESS</a></li> | + | <li><a class="paragraph-medium" href="/Team:Waterloo/Engagement/Openness">OPENNESS</a></li> |
− | <li><a href="/Team:Waterloo/Integrated_Practices">OVERVIEW</a></li> | + | <li><a class="paragraph-medium" href="/Team:Waterloo/Integrated_Practices">OVERVIEW</a></li> |
− | <li><a href="/Team:Waterloo/Integrated_Practices/Open_Science">OPEN SCIENCE</a></li> | + | <li><a class="paragraph-medium" href="/Team:Waterloo/Integrated_Practices/Open_Science">OPEN SCIENCE</a></li> |
− | <li><a href="/Team:Waterloo/Integrated_Practices/Networks">NETWORKS</a></li> | + | <li><a class="paragraph-medium" href="/Team:Waterloo/Integrated_Practices/Networks">NETWORKS</a></li> |
</ul> | </ul> | ||
Line 96: | Line 96: | ||
<ul> | <ul> | ||
<li><a href="/Team:Waterloo/Team">OUR TEAM</a></li> | <li><a href="/Team:Waterloo/Team">OUR TEAM</a></li> | ||
− | <li><a href="/Team:Waterloo/Attributions">ATTRIBUTIONS</a></li> | + | <li><a class="paragraph-medium" href="/Team:Waterloo/Attributions">ATTRIBUTIONS</a></li> |
− | <li><a href="/Team:Waterloo/Sponsors">SPONSORS</a></li> | + | <li><a class="paragraph-medium" href="/Team:Waterloo/Sponsors">SPONSORS</a></li> |
− | <li><a href="/Team:Waterloo/Collaborations">COLLABORATIONS</a></li> | + | <li><a class="paragraph-medium" href="/Team:Waterloo/Collaborations">COLLABORATIONS</a></li> |
</ul> | </ul> | ||
</nav> | </nav> |
Revision as of 03:41, 16 October 2016
Parts
This construct is a control to test the metabolic load of the Hsp104-CFP fusion protein and as a baseline against which we compare the change in the [PSI+]/[psi-] state. We synthesized a fragment to clone into the [Hsp-PRS315]. This plasmid will be referred to as the Hsp104 plasmid and is used in several of our experiments.
CFP was synthesized with a stop codon in the place of Tyr-39 (TAC -> TAG) and amplified with flanking ApaI and BamHI sites. The premature stop codon (before the CFP fluorophore) was expected to truncate the protein during normal transcription. Fluorimetry readings were then used to quantify the amount of read-through for the CFP-tagged Hsp104.
CFP was synthesized with a stop codon in the place of Val-22 (TCA -> TAG) and amplified with flanking ApaI and BamHI sites. The premature stop codon (before the CFP fluorophore) was expected to truncate the protein during normal transcription. Fluorimetry readings were then used to quantify the amount of read-through for the CFP-tagged Hsp104.
This biobrick contains a fusion of the ADH1 promoter and GFP. ADH1 is a eukaryotic promoter; the presence of ethanol induces it. The fusion between it and GFP allows the strength of the promoter to be quantized in varying concentrations of ethanol using the fluorescence of the GFP.
This biobrick is a fusion of the Gal1 promoter and GFP protein. Gal1 is a eukaryotic promoter; the presence of galactose induces it. The fusion allows the strength of the promoter to be quantized in the presence of varying concentrations of galactose using the fluorescence of the GFP.
This biobrick is a fusion of the Cup1 promoter and GFP protein. Cup1 is a eukaryotic promoter; the presence of Cu2+ induces it. The fusion allows the strength of the promoter to be quantized in the presence of varying concentrations of copper ions using the fluorescence of the GFP.
This biobrick is a fusion of the Gal1,10 promoter, Cyan Fluorescent Protein (CFP), and the chaperone protein Hsp104.
This biobrick is a fusion of the Gal1,10 promoter, Cyan Fluorescent Protein (CFP), and the chaperone protein Hsp104 with a premature stop codon introduced at position 1.
This biobrick is a fusion of the Gal1,10 promoter, Cyan Fluorescent Protein (CFP), and the chaperone protein Hsp104 with a premature stop codon introduced at position 2.
The purpose of our gene retention experiments was to observe the retention of our plasmid by the yeast cells. We used GFP-tagged Hsp104 under the influence of different promoters to study the plasmid retention. A low copy number plasmid was used to more accurately study the partitioning of plasmids into daughter cells. It was also important that we use the same plasmid as our working prototype so that the findings from this experiment could be directly applied to our other data.
This construct is the same one used in the prototype (NSC); this experiment was a positive control to show the normal retention of our construct by cells.
The purpose of our gene retention experiments was to observe the retention of our plasmid by the yeast cells. We used GFP-tagged Hsp104 under the influence of different promoters to study the plasmid retention. A low copy number plasmid was used to more accurately study the partitioning of plasmids into daughter cells. It was also important that we use the same plasmid as our working prototype so that the findings from this experiment could be directly applied to our other data.
This construct is the same one used in the prototype (NSC) except with the Gal1,10 promoter replaced by a Cup1 promoter and CFP replaced by GFP; this experiment was a positive control to show the normal retention of our constructs with Cup1 promoters by cells.
Compared to other model organisms, yeast is underrepresented in the iGEM registries. As our biobrick contribution, we characterized the ADH1 promoter. We also characterized the promoters Gal1 and Cup1 as controls against which we could compare our experiments. A high copy number plasmid was used in this case (compared to the low copy Hsp104 plasmid) to maximize the promoter activity for quantification.
Blank.
Compared to other model organisms, yeast is underrepresented in the iGEM registries. As our biobrick contribution, we characterized the ADH1 promoter. We also characterized the promoters Gal1 and Cup1 as controls against which we could compare our experiments. A high copy number plasmid was used in this case (compared to the low copy Hsp104 plasmid) to maximize the promoter activity for quantification.
Gal1 is a positively regulated promoter found on the Hsp104 plasmid. Characterization was important for us to understand the transcription rates in a normal cell in order to see the metabolic load of expression of additional Hsp104.
Compared to other model organisms, yeast is underrepresented in the iGEM registries. As our biobrick contribution, we characterized the ADH1 promoter. We also characterized the promoters Gal1 and Cup1 as controls against which we could compare our experiments. A high copy number plasmid was used in this case (compared to the low copy Hsp104 plasmid) to maximize the promoter activity for quantification.
Cup 1 is a positively regulated promoter (induced with copper) found on the Sup35 plasmid [BB8]. It is less leaky than other inducible promoters which makes it useful for the study of Sup35, allowing us to control for the amount of Sup35 in the cell to see how the PSI+ state causes further misfolding of Sup35. Characterization of this promoter was therefore important for quantification of the prion response.